Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells.
BACKGROUND
The transmissible spongiform encephalopathies, otherwise known as prion diseases, occur following the conversion of the cellular prion protein (PrPC) to an alternatively folded, disease-associated isoform (PrPSc). Recent studies suggest that this conversion occurs via a cholesterol-sensitive process, as cholesterol synthesis inhibitors reduced the formation of PrPSc and delayed the clinical phase of scrapie infection. Since polyunsaturated fatty acids also reduced cellular cholesterol levels we tested their effects on PrPSc formation in three prion-infected neuronal cell lines (ScGT1, ScN2a and SMB cells).


RESULTS
We report that treatment with docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) or the cholesterol synthesis inhibitor simvastatin reduced the amounts of free cholesterol in membrane extracts from prion-infected neuronal cells. Simvastatin reduced cholesterol production while DHA and EPA promoted the conversion of free cholesterol to cholesterol esters. Crucially, while simvastatin reduced PrPSc formation, both DHA and EPA significantly increased the amounts of PrPSc in these cells. Unlike simvastatin, the effects of DHA and EPA on PrPSc content were not reversed by stimulation of cholesterol synthesis with mevalonate. Treatment of ScGT1 cells with DHA and EPA also increased activation of cytoplasmic phospholipase A2 and prostaglandin E2 production. Finally, treatment of neuronal cells with DHA and EPA increased the amounts of PrPC expressed at the cell surface and significantly increased the half-life of biotinylated PrPC.


CONCLUSIONS
We report that although treatment with DHA or EPA significantly reduced the free cholesterol content of prion-infected cells they significantly increased PrPSc formation in three neuronal cell lines. DHA or EPA treatment of infected cells increased activation of phospholipase A2, a key enzyme in PrPSc formation, and altered the trafficking of PrPC. PrPC expression at the cell surface, a putative site for the PrPSc formation, was significantly increased, and the rate at which PrPC was degraded was reduced. Cholesterol depletion is seen as a potential therapeutic strategy for prion diseases. However, these results indicate that a greater understanding of the precise relationship between membrane cholesterol distribution, PrPC trafficking, cell activation and PrPSc formation is required before cholesterol manipulation can be considered as a prion therapeutic.
Bate
Clive
C
Department of Pathology and Infectious Diseases, Royal Veterinary College, Hawkshead Lane, North Mymms, Herts, UK, AL9 7TA. cbate@rvc.ac.uk
Tayebi
Mourad
M
Diomede
Luisa
L
Salmona
Mario
M
Williams
Alun
A
D000818:Animals; D002460:Cell Line; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000494:pharmacology*; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000494:pharmacology*; D008798:Mevalonic Acid / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism*; D064801:Phospholipase A2 Inhibitors; D054467:Phospholipases A2 / Q000378:metabolism; D018621:PrPC Proteins / Q000378:metabolism; D018620:PrPSc Proteins / Q000378:metabolism; D011328:Prions / Q000378:metabolism*; D019821:Simvastatin / Q000378:metabolism / Q000494:pharmacology
D064801:Phospholipase A2 Inhibitors; D018621:PrPC Proteins; D018620:PrPSc Proteins; D011328:Prions; D004281:Docosahexaenoic Acids; D002784:Cholesterol; D015118:Eicosapentaenoic Acid; D019821:Simvastatin; D054467:Phospholipases A2; D008798:Mevalonic Acid
Nature. 1996 Jan 25;379(6563):339-43
8552188
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9683-8
15210972
J Clin Invest. 2002 Oct;110(7):891-8
12370264
Nature. 2003 Mar 6;422(6927):80-3
12621436
Am J Clin Nutr. 2006 Dec;84(6):1277-89
17158407
Arch Biochem Biophys. 2004 Jun 15;426(2):208-24
15158671
Neuroreport. 2007 Mar 26;18(5):479-82
17496807
EMBO J. 2001 Aug 1;20(15):3957-66
11483499
J Cell Biol. 1995 Apr;129(1):121-32
7698979
J Mol Neurosci. 2000 Jun;14(3):123-35
10984188
FASEB J. 2004 Jun;18(9):1040-2
15084525
Mini Rev Med Chem. 2004 Oct;4(8):859-71
15544547
J Biol Chem. 2001 Oct 5;276(40):37335-40
11489905
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9295-9
11470893
Biochemistry. 2003 Oct 21;42(41):12028-37
14556634
Science. 2003 Oct 31;302(5646):871-4
14593181
Biochem Biophys Res Commun. 2006 Sep 22;348(2):697-702
16890918
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13363-83
9811807
Chem Phys Lipids. 2008 May;153(1):57-63
18343224
J Nutr Biochem. 2004 Nov;15(11):700-6
15590275
Neuropathol Appl Neurobiol. 1997 Apr;23(2):93-101
9160894
Science. 2000 Dec 1;290(5497):1721-6
11099405
J Biol Chem. 2004 Aug 27;279(35):36405-11
15210691
Brain. 2003 Sep;126(Pt 9):2065-73
12821516
J Biol Chem. 2002 Oct 11;277(41):38972-7
12163492
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11062-7
17573534
Annu Rev Biochem. 1997;66:613-38
9242919
J Virol. 1990 Mar;64(3):1093-101
1968104
Mol Cell Neurosci. 2006 Feb;31(2):346-53
16278084
Pharmacol Ther. 2005 Jan;105(1):7-21
15626453
BMC Biol. 2008 Feb 12;6:8
18269734
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14945-9
8962161
Biol Pharm Bull. 2007 Apr;30(4):835-8
17409533
Chem Phys Lipids. 2006 Jun;141(1-2):66-71
16647049
Exp Biol Med (Maywood). 2001 Nov;226(10):873-90
11682693
Science. 1982 Apr 9;216(4542):136-44
6801762
J Biol Chem. 2004 Apr 9;279(15):14983-90
14754889
Curr Opin Lipidol. 2002 Apr;13(2):155-64
11891418
Biochem J. 2004 Mar 1;378(Pt 2):281-92
14662007
Biochemistry. 2002 Oct 22;41(42):12868-75
12379130
Science. 2001 May 11;292(5519):1160-4
11349148